While PD-1 inhibitors have emerged as a front-line treatment for several cancers, these therapies are known to be associated with immune-related adverse events (irAE’s). In two posters presented at #isporannual last week, SmartAnalyst evaluated irAEs reported in different organ classes by NSCLC/ melanoma patients treated with PD-1 inhibitor therapies.

Click here to read more: ISPOR 2021